Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 145

1.

An insertional mutagenesis screen identifies genes that cooperate with Mll-AF9 in a murine leukemogenesis model.

Bergerson RJ, Collier LS, Sarver AL, Been RA, Lugthart S, Diers MD, Zuber J, Rappaport AR, Nixon MJ, Silverstein KA, Fan D, Lamblin AF, Wolff L, Kersey JH, Delwel R, Lowe SW, O'Sullivan MG, Kogan SC, Adams DJ, Largaespada DA.

Blood. 2012 May 10;119(19):4512-23. doi: 10.1182/blood-2010-04-281428. Epub 2012 Mar 16.

2.

MLL-AF9-induced leukemogenesis requires coexpression of the wild-type Mll allele.

Thiel AT, Blessington P, Zou T, Feather D, Wu X, Yan J, Zhang H, Liu Z, Ernst P, Koretzky GA, Hua X.

Cancer Cell. 2010 Feb 17;17(2):148-59. doi: 10.1016/j.ccr.2009.12.034.

3.

CBX8, a polycomb group protein, is essential for MLL-AF9-induced leukemogenesis.

Tan J, Jones M, Koseki H, Nakayama M, Muntean AG, Maillard I, Hess JL.

Cancer Cell. 2011 Nov 15;20(5):563-75. doi: 10.1016/j.ccr.2011.09.008.

4.

MLL-AF9 and FLT3 cooperation in acute myelogenous leukemia: development of a model for rapid therapeutic assessment.

Stubbs MC, Kim YM, Krivtsov AV, Wright RD, Feng Z, Agarwal J, Kung AL, Armstrong SA.

Leukemia. 2008 Jan;22(1):66-77. Epub 2007 Sep 13.

5.

EVI1 is critical for the pathogenesis of a subset of MLL-AF9-rearranged AMLs.

Bindels EM, Havermans M, Lugthart S, Erpelinck C, Wocjtowicz E, Krivtsov AV, Rombouts E, Armstrong SA, Taskesen E, Haanstra JR, Beverloo HB, Döhner H, Hudson WA, Kersey JH, Delwel R, Kumar AR.

Blood. 2012 Jun 14;119(24):5838-49. doi: 10.1182/blood-2011-11-393827. Epub 2012 May 2.

6.

Cooperation of MLL/AF10(OM-LZ) with PTPN11 activating mutation induced monocytic leukemia with a shorter latency in a mouse bone marrow transplantation model.

Fu JF, Liang ST, Huang YJ, Liang KH, Yen TH, Liang DC, Shih LY.

Int J Cancer. 2017 Mar 1;140(5):1159-1172. doi: 10.1002/ijc.30515. Epub 2016 Nov 25.

PMID:
27859216
7.

DOT1L, the H3K79 methyltransferase, is required for MLL-AF9-mediated leukemogenesis.

Nguyen AT, Taranova O, He J, Zhang Y.

Blood. 2011 Jun 23;117(25):6912-22. doi: 10.1182/blood-2011-02-334359. Epub 2011 Apr 26.

8.

MLL-AF9-mediated immortalization of human hematopoietic cells along different lineages changes during ontogeny.

Horton SJ, Jaques J, Woolthuis C, van Dijk J, Mesuraca M, Huls G, Morrone G, Vellenga E, Schuringa JJ.

Leukemia. 2013 Apr;27(5):1116-26. doi: 10.1038/leu.2012.343. Epub 2012 Nov 26.

PMID:
23178754
9.

Prenatal and postnatal myeloid cells demonstrate stepwise progression in the pathogenesis of MLL fusion gene leukemia.

Johnson JJ, Chen W, Hudson W, Yao Q, Taylor M, Rabbitts TH, Kersey JH.

Blood. 2003 Apr 15;101(8):3229-35. Epub 2002 Dec 19.

10.

The AAA+ ATPase RUVBL2 is a critical mediator of MLL-AF9 oncogenesis.

Osaki H, Walf-Vorderwülbecke V, Mangolini M, Zhao L, Horton SJ, Morrone G, Schuringa JJ, de Boer J, Williams O.

Leukemia. 2013 Jul;27(7):1461-8. doi: 10.1038/leu.2013.42. Epub 2013 Feb 13.

PMID:
23403462
11.

DNA structural properties of AF9 are similar to MLL and could act as recombination hot spots resulting in MLL/AF9 translocations and leukemogenesis.

Strissel PL, Strick R, Tomek RJ, Roe BA, Rowley JD, Zeleznik-Le NJ.

Hum Mol Genet. 2000 Jul 1;9(11):1671-9.

PMID:
10861294
12.

Malignant transformation initiated by Mll-AF9: gene dosage and critical target cells.

Chen W, Kumar AR, Hudson WA, Li Q, Wu B, Staggs RA, Lund EA, Sam TN, Kersey JH.

Cancer Cell. 2008 May;13(5):432-40. doi: 10.1016/j.ccr.2008.03.005.

13.

Differential requirement for wild-type Flt3 in leukemia initiation among mouse models of human leukemia.

Kamezaki K, Luchsinger LL, Snoeck HW.

Exp Hematol. 2014 Mar;42(3):192-203.e1. doi: 10.1016/j.exphem.2013.11.008. Epub 2013 Nov 20.

15.

The trithorax protein partner menin acts in tandem with EZH2 to suppress C/EBPα and differentiation in MLL-AF9 leukemia.

Thiel AT, Feng Z, Pant DK, Chodosh LA, Hua X.

Haematologica. 2013 Jun;98(6):918-27. doi: 10.3324/haematol.2012.074195. Epub 2013 Jan 24.

16.

A murine Mll-AF4 knock-in model results in lymphoid and myeloid deregulation and hematologic malignancy.

Chen W, Li Q, Hudson WA, Kumar A, Kirchhof N, Kersey JH.

Blood. 2006 Jul 15;108(2):669-77. Epub 2006 Mar 21.

17.

Downregulation of RUNX1/CBFβ by MLL fusion proteins enhances hematopoietic stem cell self-renewal.

Zhao X, Chen A, Yan X, Zhang Y, He F, Hayashi Y, Dong Y, Rao Y, Li B, Conway RM, Maiques-Diaz A, Elf SE, Huang N, Zuber J, Xiao Z, Tse W, Tenen DG, Wang Q, Chen W, Mulloy JC, Nimer SD, Huang G.

Blood. 2014 Mar 13;123(11):1729-38. doi: 10.1182/blood-2013-03-489575. Epub 2014 Jan 21.

18.

The PHD fingers of MLL block MLL fusion protein-mediated transformation.

Muntean AG, Giannola D, Udager AM, Hess JL.

Blood. 2008 Dec 1;112(12):4690-3. doi: 10.1182/blood-2008-01-134056. Epub 2008 Sep 16.

19.

The CDK9 Inhibitor Dinaciclib Exerts Potent Apoptotic and Antitumor Effects in Preclinical Models of MLL-Rearranged Acute Myeloid Leukemia.

Baker A, Gregory GP, Verbrugge I, Kats L, Hilton JJ, Vidacs E, Lee EM, Lock RB, Zuber J, Shortt J, Johnstone RW.

Cancer Res. 2016 Mar 1;76(5):1158-69. doi: 10.1158/0008-5472.CAN-15-1070. Epub 2015 Dec 1.

20.

Instructive Role of MLL-Fusion Proteins Revealed by a Model of t(4;11) Pro-B Acute Lymphoblastic Leukemia.

Lin S, Luo RT, Ptasinska A, Kerry J, Assi SA, Wunderlich M, Imamura T, Kaberlein JJ, Rayes A, Althoff MJ, Anastasi J, O'Brien MM, Meetei AR, Milne TA, Bonifer C, Mulloy JC, Thirman MJ.

Cancer Cell. 2016 Nov 14;30(5):737-749. doi: 10.1016/j.ccell.2016.10.008.

PMID:
27846391

Supplemental Content

Support Center